Financial results reveal a troubling trend; annual revenue peaked above $34 billion in 2023 but dropped to approximately $30 billion in 2025, with gross profit margins contracting from about 75% to closer to 67%. Operating results shifted from strong positive EBITDA and operating income to negative figures in recent quarters, driven by escalating expenses and interest costs.

Revenue shows a downward trend from a peak of $42.8 billion in 2023 to $30.4 billion in 2025, representing a revenue contraction of roughly 29% over two years. Quarterly revenues are inconsistent, with actual figures frequently missing analyst estimates, indicating execution difficulties or market demand weakness.

Margins have deteriorated significantly; gross margins declined from approximately 75% to 67%, while operating income margins turned negative in the last reported quarter (-10.3%). EBITDA margins swung from a healthy 25% in 2023 to nearly -10% recently, reflecting worsening cost control and increased financial burden.

Earnings quality is poor with high volatility and inconsistent profits. Recent large net losses with negative EPS disrupt prior stable earnings patterns. High interest expenses and operating costs suppress true profitability, raising concerns about sustainable earnings generation.

Year-over-year revenue decreased markedly by about 29% from 2023 to 2025, with quarterly revenue growth shifting negative recently (-9.5% YoY in the latest quarter). This reflects headwinds in demand or pricing pressures.

EPS growth has been sharply negative, falling from positive $0.28 in 2023 annualized to negative $1.27 in 2025 with recent quarters dipping into losses (e.g., -$0.23 EPS in Q1 2026). This indicates deteriorating profitability and shrinking margin contributions.

Earlier growth was fueled by scale in healthcare medical product distribution, but recent contraction likely stems from higher costs, competitive pricing pressures, and rising financial expenses.

Growth quality is weak and not sustainable at present given the negative earnings and shrinking margins combined with revenue volatility. There is no indication of recent acquisitive growth or organic expansion alleviating challenges.

Gross margin has contracted by nearly 9 percentage points from 75% to 67%, operating margins swung from +16.6% in 2023 to around -10% in the recent quarter, and net margin fell from over 14% to negative territory. EBITDA margin declined from 25% to roughly -10%.

ROE and ROA are negative currently due to net losses, undermining returns historically generated when the company was profitable. The shift to high leverage costs has pressured returns significantly.

Margins are currently unsustainable at these levels without drastic cost reductions or revenue growth. The high cost base combined with financial leverage presents a challenging environment for margin recovery.